(BIVI) Biovie - Ratings and Ratios

BioVie Inc. (NASDAQ:BIVI) is a clinical-stage biopharmaceutical company focused on developing innovative drug therapies for neurological and neurodegenerative disorders, as well as advanced liver disease. The companys pipeline includes BIV201, a drug candidate for the treatment of ascites in patients with chronic liver cirrhosis, and NE3107, a compound in Phase III clinical trials for mild to moderate Alzheimers disease. NE3107 is also being evaluated in Phase II trials for Parkinsons disease and as part of the companys long COVID program. BioVie Inc. operates in the biotechnology sector and is listed on the NASDAQ exchange.

From a financial perspective, BioVie Inc. has a market capitalization of $22.14 million, with a price-to-book ratio of 0.94. The stock has shown recent price action of $1.19, with moving averages at SMA 20: 1.52, SMA 50: 1.83, and SMA 200: 2.83. The average trading volume over 20 days is approximately 368,410 shares, with an average true range (ATR) of 0.16. The companys forward P/E is not available, reflecting its pre-revenue stage.

3-Month Forecast: - Technical Outlook: The stock may consolidate near current levels, with potential resistance at the 20-day SMA ($1.52) and support near the 50-day SMA ($1.83). A breakout above $1.52 could signal an upward trend toward the 200-day SMA ($2.83), while a breakdown below $1.00 may lead to a retest of the $0.83 level. - Fundamental Outlook: The companys focus on Alzheimers disease and liver disease treatments positions it in high-value markets with significant unmet needs. However, as a pre-revenue company, BioVie remains sensitive to clinical trial outcomes and financing requirements.